First Horizon Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $664K | Sell |
8,488
-1,403
| -14% | -$105K | 0.02% | 303 |
|
|
2025
Q1 | $717K | Sell |
9,891
-1,112
| -10% | -$79.6K | 0.02% | 284 |
|
|
2024
Q4 | $815K | Sell |
11,003
-3,308
| -23% | -$232K | 0.02% | 274 |
|
|
2024
Q3 | $944K | Sell |
14,311
-2,363
| -14% | -$172K | 0.03% | 260 |
|
|
2024
Q2 | $1.54M | Sell |
16,674
-2,855
| -15% | -$253K | 0.05% | 217 |
|
|
2024
Q1 | $1.87M | Sell |
19,529
-79,810
| -80% | -$6.7M | 0.06% | 205 |
|
|
2023
Q4 | $7.57M | Sell |
99,339
-2,343
| -2% | -$163K | 0.25% | 119 |
|
|
2023
Q3 | $7.04M | Sell |
101,682
-583
| -0.6% | -$46.9K | 0.26% | 117 |
|
|
2023
Q2 | $9.65M | Sell |
102,265
-2,015
| -2% | -$175K | 0.33% | 95 |
|
|
2023
Q1 | $8.63M | Buy |
104,280
+6,459
| +7% | +$508K | 0.31% | 98 |
|
|
2022
Q4 | $7.3M | Sell |
97,821
-1,516
| -2% | -$117K | 0.27% | 110 |
|
|
2022
Q3 | $8.21M | Buy |
99,337
+78
| +0.1% | +$7.5K | 0.33% | 96 |
|
|
2022
Q2 | $9.44M | Buy |
99,259
+9,008
| +10% | +$933K | 0.34% | 94 |
|
|
2022
Q1 | $10.6M | Sell |
90,251
-19,306
| -18% | -$2.17M | 0.58% | 48 |
|
|
2021
Q4 | $14.2M | Sell |
109,557
-1,859
| -2% | -$217K | 0.43% | 67 |
|
|
2021
Q3 | $12.6M | Buy |
111,416
+109,286
| +5,131% | +$12.5M | 0.41% | 72 |
|
|
2021
Q2 | $220K | Buy |
2,130
+357
| +20% | +$33.7K | 0.01% | 389 |
|
|
2021
Q1 | $148K | Buy |
1,773
+1,047
| +144% | +$88.5K | 0.01% | 427 |
|
|
2020
Q4 | $66K | Hold |
726
| – | – | ﹤0.01% | 516 |
|
|
2020
Q3 | $58K | Buy |
726
+120
| +20% | +$9.36K | ﹤0.01% | 504 |
|
|
2020
Q2 | $42K | Hold |
606
| – | – | ﹤0.01% | 566 |
|
|
2020
Q1 | $37K | Sell |
606
-390
| -39% | -$28.1K | ﹤0.01% | 546 |
|
|
2019
Q4 | $77K | Hold |
996
| – | – | 0.01% | 475 |
|
|
2019
Q3 | $73K | Sell |
996
-117
| -11% | -$8.22K | 0.01% | 470 |
|
|
2019
Q2 | $68K | Buy |
1,113
+720
| +183% | +$43.5K | 0.01% | 504 |
|
|
2019
Q1 | $25K | Buy |
+393
| New | +$22.4K | ﹤0.01% | 745 |
|
|
2018
Q4 | – | Sell |
-720
| Closed | -$42K | – | 1526 |
|
|
2018
Q3 | $42K | Hold |
720
| – | – | ﹤0.01% | 627 |
|
|
2018
Q2 | $35K | Buy |
+720
| New | +$33.6K | ﹤0.01% | 678 |
|
|
2017
Q1 | – | Sell |
-216
| Closed | -$6.76K | – | 1504 |
|
|
2016
Q4 | $8K | Hold |
216
| – | – | ﹤0.01% | 1048 |
|
|
2016
Q3 | $8K | Sell |
216
-234
| -52% | -$8.81K | ﹤0.01% | 1038 |
|
|
2016
Q2 | $14K | Hold |
450
| – | – | ﹤0.01% | 858 |
|
|
2016
Q1 | $14K | Hold |
450
| – | – | ﹤0.01% | 898 |
|
|
2015
Q4 | $11K | Sell |
450
-36
| -7% | -$935 | ﹤0.01% | 902 |
|
|
2015
Q3 | $11K | Buy |
486
+246
| +103% | +$5.94K | ﹤0.01% | 957 |
|
|
2015
Q2 | $6K | Hold |
240
| – | – | ﹤0.01% | 1165 |
|
|
2015
Q1 | $6K | Hold |
240
| – | – | ﹤0.01% | 1184 |
|
|
2014
Q4 | $5K | Hold |
240
| – | – | ﹤0.01% | 1224 |
|
|
2014
Q3 | $4K | Hold |
240
| – | – | ﹤0.01% | 1281 |
|
|
2014
Q2 | $3K | Buy |
+240
| New | +$3.25K | ﹤0.01% | 1315 |
|
Other funds holding EW
First Horizon Advisors's EW Position: Q2 2025 in Review
First Horizon Advisors reduced its Edwards Lifesciences (EW) stake by 14% in Q2 2025, selling an estimated $105K and leaving 8,488 shares worth $664K. The position accounts for 0.02% of the portfolio, ranked #303.
First Horizon Advisors first reported a position in EW in Q2 2014 and has held it in 39 quarters since. The position peaked at $14.2M in Q4 2021. 1,260 funds tracked by Wall St. Rank hold EW as of Q2 2025.
- First Horizon Advisors held 8,488 shares of Edwards Lifesciences worth $664K as of Q2 2025.
- First Horizon Advisors sold 1,403 Edwards Lifesciences shares in Q2 2025, an estimated $105K.
- Edwards Lifesciences made up 0.02% of First Horizon Advisors's portfolio in Q2 2025, its #303 holding.
- First Horizon Advisors first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 39 quarters since.
- First Horizon Advisors's Edwards Lifesciences position peaked at $14.2M in Q4 2021.
- 1,260 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.
Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.